PubMed_ArguminSci  

PubMed:20103725 JSONTXT 11 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T1 119-204 DRI_Background denotes Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer.
T2 205-264 DRI_Background denotes Several molecular alterations have been identified in DCIS.
T3 265-360 DRI_Background denotes Among them, cyclooxygenase 2 (COX-2) overexpression has been shown in 60% to 80% of DCIS cases.
T4 361-444 DRI_Background denotes Celecoxib is a nonsteroidal anti-inflammatory drug that selectively inhibits COX-2.
T5 445-687 DRI_Approach denotes In this study, we evaluated whether COX-2 inhibition by celecoxib can reduce the incidence of preinvasive breast cancer and its progression to invasive breast cancer in a mouse model exhibiting a similar phenotype to human solid-pattern DCIS.
T6 688-786 DRI_Approach denotes We have used the mouse model mouse mammary tumor virus (MMTV)-Neu to investigate this possibility.
T7 787-873 DRI_Background denotes These mice carry a rat Her-2/Neu transgene and are known to develop DCIS-like lesions.
T8 874-1041 DRI_Outcome denotes Our results showed that celecoxib (500 ppm) given as prophylaxis was neither able to prevent tumor development nor delay tumor appearance compared with untreated mice.
T9 1042-1199 DRI_Challenge denotes Furthermore, when the drug was given early in tumorigenesis, it did not reduce the progression of preinvasive to invasive tumors nor prevent lung metastasis.
T10 1200-1291 DRI_Background denotes Reduction of prostaglandin levels was, however, achieved in mammary tumors of treated mice.
T11 1292-1436 DRI_Background denotes In addition, celecoxib treatment caused an increase in apoptosis and decreased vascular endothelial growth factor expression in treated animals.
T12 1437-1578 DRI_Outcome denotes Our results contrast with some previously published studies and highlight the complexity of the relationship between COX-2 and breast cancer.